[1]居梦娴,方彭华,张真稳.DPP-4抑制剂相关大疱性类天疱疮的研究进展[J].国际内分泌代谢杂志,2023,43(01):46-49.[doi:10.3760/cma.j.cn121383-20210915-09044]
　Ju Mengxian,Fang Penghua,Zhang Zhenwen..Research advances of DPP-4 inhibitors associated bullous pemphigoid[J].International Journal of Endocrinology and Metabolism,2023,43(01):46-49.[doi:10.3760/cma.j.cn121383-20210915-09044]
点击复制

DPP-4抑制剂相关大疱性类天疱疮的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年01期
页码:
46-49
栏目:
综述
出版日期:
2023-01-20

文章信息/Info

Title:
Research advances of DPP-4 inhibitors associated bullous pemphigoid
作者:
居梦娴1; 方彭华2; 张真稳1
1扬州大学临床医学院内分泌科,扬州 225001; 2南京中医药大学第一临床医学院临床医学实验研究中心,南京 210023
Author(s):
Ju Mengxian1;  Fang Penghua2; Zhang Zhenwen1.
1Department of Endocrinology, Clinical Medical College of Yang Zhou University, Yangzhou 225001, China; 2 The Experimental Research Center of Clinical Medicine, The First Medical School of Nanjing University of Chinese Medicine, Nanjing 210023, China
关键词:
二肽基肽酶-4抑制剂;  大疱性类天疱疮
Keywords:
Dipeptidyl peptidase-4 inhibitors;  Bullous pemphigoid
DOI:
10.3760/cma.j.cn121383-20210915-09044
摘要:
新型口服降糖药物二肽基肽酶-4(DPP-4)抑制剂可通过抑制DPP-4活性,提高体内内源性胰高血糖素样肽-1水平,增强肠促胰岛素作用从而维持机体的血糖稳态。除有效降低血糖水平外,它还起到保护胰岛功能,延缓疾病病程的作用。近年来,众多流行病学研究发现,DPP-4抑制剂可诱导大疱性类天疱疮(BP)的发生,在临床诊疗中,对于新发或是突然加重的BP患者,应警惕药物诱发的可能性。通过对DPP-4抑制剂、BP诊断及机制、DPP-4抑制剂相关BP的免疫特征及发病机制等方面展开综述,旨在为这类患者的诊疗提供理论性依据。
Abstract:
DPP-4 inhibitors, a novel oral hypoglycemic drug, can enhance endogenous glucagon-like peptide-1 level and enhance incretin action to maintain blood glucose homeostasis by inhibiting DPP-4 enzyme activity. In addition to effectively lowering blood glucose level, it also plays a role in protecting pancreatic islets and delaying the course of disease. In recent years, a number of epidemiological studies have found that DPP-4 inhibitors can induce the occurrence of bullous pemphigoid(BP). In clinical diagnosis and treatment, the possibility of drug induction should be vigilant for patients with new or suddenly aggravated BP. DPP-4 inhibitors, diagnosis and mechanism of BP, immune characteristics and pathogenesis of DPP-4 inhibitor-associated BP are reviewed, in order to provide theoretical basis for the diagnosis and treatment of such patients.

参考文献/References:

[1] Miyamoto D,Santi CG,Aoki V,et al.Bullous pemphigoid[J].An Bras Dermatol,2019,94(2):133-146.DOI:10.1590/abd1806-4841.20199007.
[2] Liu SD,Chen WT,Chi CC.Association between medication use and bullous pemphigoid:a systematic review and meta-analysis[J].JAMA Dermatolo,2020,156(8):891-900.DOI:10.1001/jamadermatol.2020.1587.
[3] Phan K,Charlton O,Smith SD.Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid:a systematic review and adjusted meta-analysis[J].Australas J Dermatol,2020,61(1):e15-e21.DOI:10.1111/ajd.13100.
[4] Bastuji-Garin S,Joly P,Lemordant P,et al.Risk factors for bullous pemphigoid in the elderly:a prospective case-control study[J].J Invest Dermatol,2011,131(3):637-643.DOI:10.1038/jid.2010.301.
[5] Schmidt E,Spindler V,Eming R,et al.Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016[J].J Invest Dermatol,2017,137(6):1199-1203.DOI:10.1016/j.jid.2017.01.028.
[6] Carnovale C,Mazhar F,Arzenton E,et al.Bullous pemphigoid induced by dipeptidyl peptidase-4(DPP-4)inhibitors:a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase[J].Expert Opin Drug Saf,2019,18(11):1099-1108.DOI:10.1080/14740338.2019.1668373.
[7] Egami S,Yamagami J,Amagai M.Autoimmune bullous skin diseases, pemphigus and pemphigoid[J].J Allergy Clin Immunol,2020,145(4):1031-1047.DOI:10.1016/j.jaci.2020.02.013.
[8] Kridin K.Dipeptidyl-peptidase IV inhibitors(DPP4i)-associated bullous pemphigoid:Estimating the clinical profile and exploring intraclass differences[J].Dermatol Ther,2020,33(4):e13790.DOI:10.1111/dth.13790.
[9] Silverii GA,Dicembrini I,Nreu B,et al.Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials[J].Endocrine,2020,69(3):504-507.DOI:10.1007/s12020-020-02272-x.
[10] Armanious M,Abuhilal M.Gliptin-Induced bullous pemphigoid:Canadian case series of 10 patients[J].J Cutan Med Surg,2021,25(2):163-168.DOI:10.1177/1203475420972349.
[11] Kaku K,Kisanuki K,Shibata M,et al.Benefit-Risk assessment of alogliptin for the treatment of type 2 diabetes mellitus[J].Drug Saf,2019,42(11):1311-1327.DOI:10.1007/s40264-019-00857-8.
[12] Kridin K,Cohen AD.Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid:a systematic review and meta-analysis[J].J Am Acad Dermatol,2021,85(2):501-503.DOI:10.1016/j.jaad.2018.09.048.
[13] St?der S, Schmidt E, Zillikens D,et al.More severe erosive phenotype despite lower circulating autoantibody levels in dipeptidyl peptidase-4 inhibitor(DPP4i)-associated bullous pemphigoid:a retrospective cohort study[J].Am J Clin Dermatol,2021,22(1):117-127.DOI:10.1007/s40257-020-00563-7.
[14] Nieto-Benito LM,Bergón-Sendín M,Pulido-Pérez A,et al.Defining dipeptidyl peptidase-4 inhibitors-related bullous pemphigoid:a single-centre retrospective study[J].Exp Dermatol,2021,30(9):1345-1351.DOI:10.1111/exd.14387.
[15] Mai Y,Nishie W,Izumi K,et al.Preferential reactivity of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid autoantibodies to the processed extracellular domains of BP180[J].Front Immunol,2019,10:1224.DOI:10.3389/fimmu.2019.01224.
[16] Ujiie H,Muramatsu K,Mushiroda T,et al.HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors[J].J Invest Dermatol,2018,138(5):1201-1204.DOI:10.1016/j.jid.2017.11.023.
[17] Suezawa M,Dainichi T,Kaku Y,et al.Dipeptidyl peptidase 4 inhibitor-associated mucous membrane pemphigoid[J].J Dermatol,2021,48(10):1584-1587.DOI:10.1111/1346-8138.16061.
[18] Hopsu-Havu VK,Glenner GG.A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide[J].Histochemie,1966,7(3):197-201.DOI:10.1007/BF00577838.
[19] Lindgren O,Varpuluoma O,Tuusa J,et al.Gliptin-associated bullous pemphigoid and the expression of dipeptidyl peptidase-4/CD26 in bullous pemphigoid[J].Acta Derm Venereol,2019,99(6):602-609.DOI:10.2340/00015555-3166.
[20] Hayashi M,Tsunoda T,Sato F,et al.Clinical and immunological characterization of 14 cases of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid:a single-centre study[J].Br J Dermatol,2020,182(3):806-807.DOI:10.1111/bjd.18516.
[21] Chouchane K,Di Zenzo G,Pitocco D,et al.Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin[J].J Transl Med,2021,19(1):520.DOI:10.1186/s12967-021-03192-8.
[22] García-Díez I,Ivars-Lleó M,López-Aventín D,et al.Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors.Eight cases with clinical and immunological characterization[J].Int J Dermatol,2018,57(7):810-816.DOI:10.1111/ijd.14005.

备注/Memo

备注/Memo:
通信作者:张真稳,Email:zwzhang@yzu.edu.cn
基金项目:国家自然科学基金(81803792); 江苏省中医药科技发展计划项目(YB2020087)
更新日期/Last Update: 2023-01-30